Financial Position - As of September 30, 2024, CalciMedica, Inc. reported cash, cash equivalents, and short-term investments totaling $14.6 million[2]. Financial Reporting - The financial estimates are preliminary and unaudited, subject to change upon completion of the financial statement closing procedures[3]. - The independent registered public accounting firm has not audited or reviewed the preliminary results, providing no assurance on them[4]. - CalciMedica plans to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, on or about November 14, 2024[4]. Public Offering - On October 30, 2024, CalciMedica announced a proposed underwritten public offering of its common stock[5]. - During the proposed public offering, CalciMedica suspended offerings under the existing Sales Agreement, which remains in effect[6]. - The company will not make any sales of common stock under the Sales Agreement until a new prospectus supplement is filed with the SEC[6]. Forward-Looking Statements - Forward-looking statements regarding the public offering and other expectations are subject to various risks and uncertainties[9]. - Actual results may differ materially from forward-looking statements due to factors affecting CalciMedica's business[10]. - The company assumes no obligation to update forward-looking statements except as required by law[11].
CalciMedica(CALC) - 2024 Q3 - Quarterly Results